Equities Analysts Set Expectations for TWST FY2025 Earnings

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for Twist Bioscience in a research report issued on Monday, May 5th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($2.24) per share for the year, down from their previous estimate of ($2.23). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share. Leerink Partnrs also issued estimates for Twist Bioscience's Q4 2025 earnings at ($0.47) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.68) EPS.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%.

Other equities research analysts have also issued research reports about the company. Barclays lowered their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. The Goldman Sachs Group reduced their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Robert W. Baird dropped their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $50.40.

Twist Bioscience Trading Down 5.5 %

Shares of TWST traded down $1.79 during mid-day trading on Thursday, reaching $30.82. The company's stock had a trading volume of 1,158,651 shares, compared to its average volume of 968,895. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.85 billion, a PE ratio of -9.12 and a beta of 2.54. The company's fifty day moving average price is $38.63 and its two-hundred day moving average price is $43.69. Twist Bioscience has a 52 week low of $30.72 and a 52 week high of $60.90.

Insider Buying and Selling

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares of the company's stock, valued at $5,355,609.92. This trade represents a 0.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Dennis Cho sold 689 shares of the business's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $25,940.85. Following the completion of the transaction, the insider now directly owns 110,849 shares in the company, valued at $4,173,464.85. This trade represents a 0.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,991 shares of company stock valued at $742,654 over the last 90 days. Company insiders own 3.01% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TWST. First Light Asset Management LLC bought a new position in Twist Bioscience during the fourth quarter valued at $56,984,000. Marshall Wace LLP increased its position in shares of Twist Bioscience by 15,927.8% during the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock worth $39,319,000 after acquiring an additional 840,828 shares during the period. ARK Investment Management LLC increased its holdings in Twist Bioscience by 11.5% during the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock worth $245,045,000 after purchasing an additional 645,730 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after buying an additional 532,040 shares during the period. Finally, Jennison Associates LLC increased its position in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock valued at $31,636,000 after purchasing an additional 302,884 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.